Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 101–200 of 1,171
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot‐Loza, C., & Gaussem, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313079 · Cited by 80
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 81
Lettino, M., Mascherbauer, J., Nordaby, M., Ziegler, A., Collet, J., Dérumeaux, G., Hohnloser, S. H., Leclercq, C., O’Neill, D. E., Visseren, F. L. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac033 · Cited by 87
Roberts, J., Pritchard, A. L., Treweeke, A. T., Rossi, A. G., Brace, N., Cahill, P. A., MacRury, S. M., Wei, J., & Megson, I. L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.629933 · Cited by 72
Ballerini, P., Contursi, A., Bruno, A., Mucci, M., Tacconelli, S., & Patrignani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838079 · Cited by 75
Does low-dose aspirin initiated before 11 weeks’ gestation reduce the rate of preeclampsia?
Chaemsaithong, P., Cuenca-Gómez, D., Plana, N., Gil, M. M., & Poon, L. C. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.08.047 · Cited by 80
Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management
Nikolopoulos, D., Fanouriakis, A., & Boumpas, D. T. (2019) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.30.1.7 · Cited by 76
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
Sterpetti, A. V. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00891-3 · Cited by 65
Coley, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Prospects for the Primary Prevention of Myocardial Infarction and Stroke
Caldwell, M., Martinez, L. C., Foster, J. G., Sherling, D. H., & Hennekens, C. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418817344 · Cited by 79
Seidu, S., Kunutsor, S. K., Sesso, H. D., Gaziano, J. M., Buring, J. E., Roncaglioni, M. C., & Khunti, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0875-4 · Cited by 71
Colafella, K. M. M., Neuman, R. I., Visser, W., Danser, A. H. J., & Versmissen, J. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13308 · Cited by 74
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 74
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
Chow, J. H., Rahnavard, A., Gomberg‐Maitland, M., Chatterjee, R., Patodi, P., Yamane, D. P., Levine, A. R., Davison, D. L., Hawkins, K., Jackson, A. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3890 · Cited by 63
Update on Management of Cardiovascular Diseases in Women
Lucà, F., Abrignani, M. G., Parrini, I., Fusco, S. A. D., Giubilato, S., Rao, C. M., Piccioni, L., Cipolletta, L., Passaretti, B., Giallauria, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051176 · Cited by 70
Realising the full potential of data-enabled trials in the UK: a call for action
Sydes, M. R., Barbáchano, Y., Bowman, L. J., Denwood, T., Farmer, A. A., Garfield-Birkbeck, S., Gibson, M., Gulliford, M. C., Harrison, D. A., Hewitt, C. E., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043906 · Cited by 63
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 69
Boakye, E., Uddin, S. M. I., Obisesan, O. H., Osei, A. D., Dzaye, O. D. A., Sharma, G. V., McEvoy, J. W., Blumenthal, R. S., & Blaha, M. J. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100256 · Cited by 58
The need for increased pragmatism in cardiovascular clinical trials
Usman, M., Spall, H. G. C. V., Greene, S. J., Pandey, A., McGuire, D. K., Ali, Z. A., Mentz, R. J., Fonarow, G. C., Spertus, J. A., Anker, S. D., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00705-w · Cited by 65
Clinical practice guideline for the management of hypertension in China
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 68
Jacobsen, A. P., Raber, I., McCarthy, C. P., Blumenthal, R. S., Bhatt, D. L., Cusack, R., Serruys, P. W. J. C., Wijns, W. C., & McEvoy, J. W. (2020) · Circulation · doi:10.1161/circulationaha.120.045695 · Cited by 62
Capodanno, D., & Angiolillo, D. J. (2020) · Circulation · doi:10.1161/circulationaha.120.045465 · Cited by 65
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 62
Long-term aspirin use and cancer risk: a 20-year cohort study
Skriver, C., Maltesen, T., Dehlendorff, C., Skovlund, C. W., Schmidt, M., Sørensen, H. T., & Friis, S. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad231 · Cited by 67
Petrucci, G., Zaccardi, F., Giaretta, A., Cavalca, V., Capristo, E., Cardillo, C., Pitocco, D., Porro, B., Schinzari, F., TOFFOLO, G. M., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14445 · Cited by 57
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Schäfer, A., Flierl, U., Berliner, D., & Bauersachs, J. K. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06981-3 · Cited by 66
Dovizio, M., Ballerini, P., Fullone, R., Tacconelli, S., Contursi, A., & Patrignani, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249585 · Cited by 61
Manchikanti, L. (2019) · Pain Physician · doi:10.36076/ppj/2019.22.s75 · Cited by 73
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 56
Jungo, K. T., Mantelli, S., Rozsnyai, Z., Μίσσιου, Α., Kitanovska, B. G., Weltermann, B., Mallen, C. D., Collins, C., Bonfim, D., Kurpas, D., et al. (2021) · BMC Geriatrics · doi:10.1186/s12877-020-01953-6 · Cited by 61
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 66
Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
Cofer, L. B., Barrett, T. J., & Berger, J. S. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318020 · Cited by 62
Olesen, K. K. W., Madsen, M., Gyldenkerne, C., Thrane, P. G., Würtz, M., Thim, T., Jensen, L. O., Eikelboom, J. W., Bøtker, H. E., Sørensen, H. T., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.026099 · Cited by 61
Rationale and Design of SCOT-HEART 2 Trial
McDermott, M., Meah, M. N., Khaing, P. H., Wang, K.-L., Ramsay, J., Scott, G., Rickman, H., Burt, T., McGowan, I., Fairbairn, T. A., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.05.016 · Cited by 65
Influence of Sex on Platelet Reactivity in Response to Aspirin
Friede, K. A., Infeld, M. M., Tan, R., Knickerbocker, H. J., Myers, R. A., Dubois, L. G., Thompson, J. W., Kaddurah‐Daouk, R., Ginsburg, G. S., Ortel, T. L., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014726 · Cited by 52
German, C. A., Baum, S. J., Ferdinand, K. C., Gulati, M., Polonsky, T. S., Toth, P. P., & Shapiro, M. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100432 · Cited by 60
Jang, H., Lee, Y. B., Moon, H., Chung, J., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, Y. J., Lee, J., et al. (2022) · Hepatology · doi:10.1002/hep.32380 · Cited by 53
Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature
Stewart, J., Addy, K., Campbell, S., & Wilkinson, P. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020949326 · Cited by 82
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective
Rocca, B., & Patrono, C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108008 · Cited by 48
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 60
The limitations of observation studies for decision making regarding drugs efficacy and safety
Gueyffier, F., & Cucherat, M. (2018) · Therapies · doi:10.1016/j.therap.2018.11.001 · Cited by 56
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease
Marquis‐Gravel, G., Roe, M. T., Harrington, R. A., Muñoz, D., Hernandez, A. F., & Jones, W. S. (2019) · Circulation · doi:10.1161/circulationaha.119.040205 · Cited by 51
Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress
Vaidya, A. R., Wolska, N., Vara, D. S., Mailer, R. K., Schröder, K., & Pula, G. (2021) · Antioxidants · doi:10.3390/antiox10050706 · Cited by 56
Aspirin in the Modern Era of Cardiovascular Disease Prevention
Murphy, E., Curneen, J. M. G., & McEvoy, J. W. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.293 · Cited by 53
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus
Hussain, S. T., & Chowdhury, T. A. (2019) · Drugs · doi:10.1007/s40265-019-1061-4 · Cited by 58
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 48
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review
Liang, P. S., Shaukat, A., & Crockett, S. D. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.014 · Cited by 48
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction
Thorp, E. B., & Filipp, M. E. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023405 · Cited by 51
Kelly, D., & Rothwell, P. M. (2019) · Kidney International · doi:10.1016/j.kint.2019.09.024 · Cited by 49
Differences in the prevention and control of cardiovascular and cerebrovascular diseases
Liu, C., Du, L., Wang, S., Kong, L., Zhang, S., Li, S., Zhang, W., & Du, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105737 · Cited by 47
Aspirin in Primary Prevention of Cardiovascular Events
Soodi, D., VanWormer, J. J., & Rezkalla, S. H. (2020) · Clinical Medicine & Research · doi:10.3121/cmr.2020.1548 · Cited by 54
Overview of Aspirin and Platelet Biology
Santos‐Gallego, C. G., & Badimón, J. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.018 · Cited by 55
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
Bainey, K. R., Marquis‐Gravel, G., Belley‐Côté, E. P., Turgeon, R. D., Ackman, M. L., Babadagli, H. E., Bewick, D. J., Boivin‐Proulx, L., Cantor, W. J., Fremes, S. E., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.10.013 · Cited by 65
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Parker, W. A., Schulte, C., Barwari, T., Phoenix, F. A., Pearson, S. M., Mayr, M., Grant, P. J., Storey, R. F., & Ajjan, R. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0981-3 · Cited by 43
Bellinge, J. W., Francis, R. J., Lee, S. C., Phillips, M. R., Rajwani, A., Lewis, J. R., Watts, G. F., & Schultz, C. J. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315364 · Cited by 45
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
Parish, S., Mafham, M., Offer, A., Barton, J., Wallendszus, K., Stevens, W., Buck, G., Haynes, R., Collins, R., Bowman, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac179 · Cited by 40
“Participants and procedures CONSORT guidelines for reporting have been followed (see Supplementary material online, Table S1 and Methods S1).(12,13,15) Full details of the study procedures have been reported previously.”
InfluentialAspirin in the Prevention of Cardiovascular Disease and Cancer
Ricciotti, E., & FitzGerald, G. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-051019-102940 · Cited by 46
Selak, V., Jackson, R., Poppe, K., Wu, B., Harwood, M. L. N., Grey, C., Pylypchuk, R. D., Mehta, S., Kerr, A., & Wells, S. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2808 · Cited by 42
Planek, M. I. C., Silver, A. J., Volgman, A. S., & Okwuosa, T. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014668 · Cited by 41
CYP2C19 Genotype-Guided Antiplatelet Therapy: Promises and Pitfalls
Ellithi, M., Baye, J. F., & Wilke, R. A. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0046 · Cited by 46
Schnabel, R. B., Benezet‐Mazuecos, J., Becher, N., McIntyre, W. F., Fierenz, A., Lee, S. F., Goette, A., Atar, D., Bertaglia, E., Benz, A. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae596 · Cited by 45
Renda, G., Patti, G., Lang, I. M., Siller-Matula, J. M., Hylek, E. M., Ambrosio, G., Haas, S. K., & Caterina, R. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.004 · Cited by 42
Sinclair, A. J., Dunning, T. L., Dhatariya, K., & an International Group of Experts (2019) · Diabetic Medicine · doi:10.1111/dme.14135 · Cited by 46
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
Calderone, D., Greco, A., Ingala, S., Agnello, F. G., Franchina, A. G., Scalia, L., Buccheri, S., & Capodanno, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1667-7427 · Cited by 41
The year in cardiology 2018: prevention
Reiner, Ž., Laufs, U., Cosentino, F., & Landmesser, U. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy894 · Cited by 50
Veronese, N., Demurtas, J., Thompson, T., Solmi, M., Pesolillo, G., Celotto, S., Barnini, T., Stubbs, B., Maggi, S., Pilotto, A., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14310 · Cited by 39
Clinical endpoint adjudication
Meah, M. N., Denvir, M. A., Mills, N. L., Norrie, J. D., & Newby, D. E. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30635-8 · Cited by 38
Godiér, A., Albaladejo, P., & the French Working Group on Perioperative Haemostasis (GIHP) Group (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072318 · Cited by 37
Self-citationThe Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, M., Uribe, J., Olvares, N., Huerta, P., Cabrera, D., & Romero‐Gómez, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101501 · Cited by 41
Hall, K. T., Kessler, T., Buring, J. E., Passow, D., Sesso, H. D., Zee, R. Y. L., Ridker, P. M., Chasman, D. I., & Schunkert, H. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz384 · Cited by 42
Sternkopf, M., Nagy, M., Baaten, C. C. F. M. J., Kuijpers, M. J. E., Tullemans, B. M. E., Wirth, J., Theelen, W., Mastenbroek, T. G., Lehrke, M., Winnerling, B., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313645 · Cited by 35
Diabetes and Platelet Response to Low-dose Aspirin
Al‐Sofiani, M. E., Yanek, L. R., Faraday, N. R., Kral, B. G., Mathias, R. A., Becker, L. C., Becker, D. M., Vaidya, D. M., & Kalyani, R. R. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01254 · Cited by 37
Sohn, M., & Lim, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052593 · Cited by 41
Boccatonda, A., Cane, L. D., Marola, L., D’Ardes, D., Lessiani, G., Gregorio, N. D., Ferri, C., Cipollone, F., Serra, C., Santilli, F., et al. (2024) · Life · doi:10.3390/life14040473 · Cited by 40
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
Use of Preventive Aspirin Among Older US Adults With and Without Diabetes
Liu, E. Y., Al‐Sofiani, M. E., Yeh, H., Echouffo-Tcheugui, J. B., Joseph, J. J., & Kalyani, R. R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.12210 · Cited by 35
Harper, C., Mafham, M. M., Herrington, W. G., Staplin, N., Stevens, W., Wallendszus, K., Haynes, R., Landray, M., Parish, S., Bowman, L. J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.39748 · Cited by 36
Sueldo, M. D., Rivera, M. A. M., Sanchez-Zambrano, M. B., Zilberman, J. M., Múnera, A. G., Paniagua, M., Campos-Alcántara, L., Almonte, C., Paix-Gonzales, A., Anchique-Santos, C. V., et al. (2022) · Archivos de cardiología de México · doi:10.24875/acm.22000071 · Cited by 59
Joharatnam‐Hogan, N., Hatem, D., Cafferty, F. H., Petrucci, G., Cameron, D., Ring, A. E., Kynaston, H., Gilbert, D. C., Wilson, R. H., Hubner, R. A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02310-1 · Cited by 35
Gigante, B., Tamargo, J. L., Agewall, S., Atar, D., ten Berg, J. M., Campo, G. C., Cerbai, E., Christersson, C., Dobrev, D., Ferdinandy, P., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae064 · Cited by 42
Slipczuk, L. N., Blankstein, R., Bucciarelli‐Ducci, C., Braun, L. T., Phillips, L. M., Piña, P., Shaw, L. J., Tamis‐Holland, J. E., Williamson, E. E., & Virani, S. S. (2025) · Circulation · doi:10.1161/cir.0000000000001394 · Cited by 47
Wang, T., Wu, J., Dong, W., Wang, M., Zhong, X., Zhang, W., Dai, L., Xie, Y., Liu, Y., He, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60459 · Cited by 33
Endothelial YAP Mediates Hyperglycemia-Induced Platelet Hyperactivity and Arterial Thrombosis
Li, Z., Zhang, J., Ma, Z., Zhao, G., He, X., Yu, X., Fu, Q., Wu, N., Ding, Z., Sun, H., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319835 · Cited by 38
Antithrombotic Drugs—Pharmacology and Perspectives
Li, T., Deshan, Y., & Yuan, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_4 · Cited by 36
A Comprehensive Update on Aspirin Management During Noncardiac Surgery
Gerstein, N. S., Albrechtsen, C. L., Mercado, N. F., Cigarroa, J. E., & Schulman, P. M. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005064 · Cited by 35
Wang, Y., Han, S., Qin, H., Zheng, H., Jiang, B., Cao, Y., Gao, Y., Guan, L., Jia, Q., Jiang, Y., et al. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000385 · Cited by 35
Estándares SEA 2022 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.11.003 · Cited by 70
Broni, E. K., Ndumele, C. E., Echouffo-Tcheugui, J. B., Kalyani, R. R., Bennett, W. L., & Michos, E. D. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01444-x · Cited by 35
Autoren, & Collaborators: (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1975-0414 · Cited by 33
Angiolillo, D. J., & Capodanno, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.022 · Cited by 29
Chaudhary, R., Bashline, M. J., Novelli, E. M., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.050 · Cited by 30
Wang, X., Mobley, A., Țica, O., Okoth, K., Ghosh, R. E., Myles, P. R., Williams, T., Haynes, S., Nirantharakumar, K., Shukla, D., et al. (2022) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztac046 · Cited by 34
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
Mann, J. F. E., Joseph, P., Gao, P., Pais, P., Tyrwhitt, J., Xavier, D., Dans, T., López-Jaramillo, P. A., Gamra, H., & Yusuf, S. (2022) · Kidney International · doi:10.1016/j.kint.2022.09.023 · Cited by 31
Evidence-Based Management of Diabetes in Older Adults
Mooradian, A. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0598-3 · Cited by 34
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.